Summary of interview
At the launch of the Guide to Immunopharmacology (http://www.guide toimmunopharmacology.org/immuno/index.jsp) created by the International Union of Basic and Clinical Pharmacology (IUPHAR) in conjunction with the International Union of Immunological Societies (IUIS), Professor Michael Spedding first explained the concept behind the initiative. This database builds on the established Guide to Pharmacology (http://www.guidetopharmacology.org/index.jsp), which contains quantitative information on drug targets and the best medications acting on them, both clinically and experimentally.
The new Guide to Immunopharmacology is a freely available database built up over the past 3 years with the intention of linking together all immunopharmacological targets, along with their associated cell types. This guide will be continually evolving, but such improvements are dependent on the efforts of those using the database. Professor Spedding also noted that IUPHAR has restructured modern pharmacology by producing 120 articles involving all the main receptor systems, with a h-index of 80. Of direct interest to the cardiovascular community, Professor Spedding highlighted the IUPHAR's Pharmacology Education Project, a freely available website with information pertinent to the cardiovascular system and relevant therapies.
The role of immunopharmacology has been expanding in recent years, and targeting immune responses is an emerging theme in cardiovascular medicine. In relation to this, Professor Mantovani spoke about the complimentary nature of the partnership between the IUIS and the IUPHAR: each specializing in their respective domains of basic immunology and inflammation, and pharmacology. The Guide to Immunopharmacology therefore represents the synergy and union of two communities and knowledgebases. Professor Spedding noted that a key area being addressed is the simplification of immunopharmacology-related vocabulary for younger generations.
Turning to the question of the biggest challenges and most promising perspectives in immunopharmacology, Professor Mantovani spoke about how we live in a time when the role of inflammation and immunity in degenerative diseases, such as cancer and cardiovascular diseases, is both recognized and appreciated. This can be seen by the recent 2018 Nobel Prize in medicine being award to James P. Allison and Tasuku Honjo for their work on immune checkpoints in cancer therapy. The challenges ahead towards tackling such issues therefore relies on the kind of multi-level interaction and complementarity which the partnership between the IUIS and IUPHAR reflects, as well as the discovery of new therapeutic tools and targets. 
